Growth Hormone News and Research

RSS

Growth hormone (GH) is a protein-based peptide hormone. It stimulates growth, cell reproduction and regeneration in humans and other animals. Growth hormone is a 191-amino acid, single-chain polypeptide that is synthesized, stored, and secreted by the somatotroph cells within the lateral wings of the anterior pituitary gland.

Aeterna Zentaris' AEZS-130 demonstrates potential as oral diagnostic test for AGHD

Aeterna Zentaris Inc., today announced that an interim review of a Phase 3 trial of AEZS-130 (macimorelin, SolorelTM), demonstrates the compound may provide a simple, well-tolerated and safe oral diagnostic test for Adult Growth Hormone Deficiency (AGHD). The data was presented earlier today by Beverly M.K. Biller, M.D. of the Harvard Medical School/Massachusetts General Hospital in Boston, at the 5th International Congress of the Growth Hormone Research Society (GRS) and the Insulin-like Growth Factors (IGF) Society in New York City.

6 Oct 2010

FDA grants orphan drug designation to hGH-CTP for treating growth hormone deficiency

PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to hGH-CTP, PROLOR's longer-acting version of human growth hormone for the treatment of growth hormone deficiency.

5 Oct 2010

Novo Nordisk announces $73M expansion of Clayton insulin delivery systems manufacturing facility

Novo Nordisk, a global healthcare company and leader in diabetes care, today announced a $73 million expansion of its Clayton, NC manufacturing facility to accommodate increased production capacity for the Company's insulin delivery devices.

5 Oct 2010

Human growth hormone can treat cystic fibrosis symptoms

Human growth hormone can be used successfully to treat some symptoms of cystic fibrosis, but its impact on the disease itself remains unknown, according to a new report funded by HHS' Agency for Healthcare Research and Quality (AHRQ).

5 Oct 2010

Study may provide informed use of growth hormone in muscle development, muscle loss

Growth hormone is used to treat children's growth disorders and has been used by some sports men and women to promote muscle growth and regeneration. This is because it coordinates skeletal muscle development, nutrient uptake, and nutrient utilization. It is not clear, however, which of these effects are direct and which are indirectly mediated via growth hormone induction of the protein IGF-1.

4 Oct 2010

Over one in three diabetics do not take insulin as prescribed

More than one in three diabetes patients skip doses or fail to take their insulin as prescribed, stating that they have done so on average three times in the last month, and 77 percent of physicians estimate that in reality this number could be as high as six doses, according to the Global Attitudes of Patients and Physicians in Insulin Therapy (GAPP™) survey, released today by Novo Nordisk.

23 Sep 2010

Dr. Shlomo Melmed awarded 9th Endocrine Regulation Prize of the Fondation Ipsen

The international jury under the presidency of Professor Iain Robinson (National Institute for Medical Research, London, UK) awarded today the 9th Endocrine Regulation Prize of the Fondation Ipsen (20.000€) to Dr. Shlomo Melmed (Cedars-Sinai Medical Center, Los Angeles, USA) during the annual congress of the ENEA (European NeuroEndocrine Association) in Liège (Belgium), for his translational approach to endocrinology. Shlomo Melmed is an internationally recognized endocrinologist and an authority on pituitary medicine.

22 Sep 2010

Diplomat Specialty Pharmacy ranked #554 on Inc.'s Top 5000 list of fastest-growing private companies

Diplomat Specialty Pharmacy announced today they have earned a position of 554 on Inc. Magazine's exclusive, annual ranking of the fastest-growing private companies in America.

10 Sep 2010

Scientists develop new strategy for quicker detection of biomarkers that indicate disease

Scientists at the UK's National Physical Laboratory have developed a new strategy for quicker and more precise detection of biomarkers - proteins which indicate disease. The work could pave the way for new tools to detect early stages of Alzheimer's and cancer at the molecular level.

9 Sep 2010

World's tallest man undergoes Gamma Knife surgery

Much of Sultan Kosen's eight feet, two-inch stature rose up in an 17-year period starting at age 10, when the benign tumor in his brain's pituitary gland highjacked the organ, causing it to secrete massive amounts of growth hormone, making Mr. Kosen's body grow fast and grow without ceasing. He will need to wait several months to find out if his Gamma Knife® surgery last Thursday at the University of Virginia (UVA, Charlottesville, Va.) has inactivated the tumor and he has reached his final height, but his physicians are optimistic.

27 Aug 2010

Researchers recommend traumatic brain injury reclassification for additional funding

Traumatic brain injury, currently considered a singular event by the insurance industry and many health care providers, is instead the beginning of an ongoing process that impacts multiple organ systems and may cause or accelerate other diseases and disorders that can reduce life expectancy, according to research from the University of Texas Medical Branch at Galveston.

27 Aug 2010

Access Pharmaceuticals to highlight Cobalamin nanotechnology at ACS National Meeting

ACCESS PHARMACEUTICALS, INC.,a biopharmaceutical company specializing in products for cancer and supportive care, announced that its Director of Chemistry and Quality, Dr. Ric Zarzycki will give an invited presentation today on the Company's Cobalamin nanoparticle technology at a thought-leadership symposium being held at the American Chemical Society's ("ACS") 240th National Meeting & Exposition, at Boston Convention and Exhibition Center in Boston, Massachusetts, August 22-26, 2010.

25 Aug 2010

FDA clears PROLOR Biotech's Phase II clinical trial of hGH-CTP

PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced that it has received regulatory clearance from the U.S. Food and Drug Administration (FDA) to conduct a Phase II clinical trial in the U.S. of its longer-acting version of human growth hormone, hGH-CTP.

24 Aug 2010

Novo Nordisk reaches exclusive agreement to market Vagifem 10 mcg

Novo Nordisk Inc. today announced that it has signed an exclusive agreement with Upsher-Smith Laboratories, Inc. to market Vagifem (estradiol vaginal tablets) 10 mcg. Under the terms of the agreement, Upsher-Smith will exclusively market Vagifem 10 mcg to physicians in the U.S. beginning August 2 through the company's existing field sales force.

23 Aug 2010

Antares Pharma second-quarter total revenue increases 78% to $3.1 million

Antares Pharma, Inc. today reported financial and operating results for the second quarter ended June 30, 2010.

13 Aug 2010

Aeterna Zentaris second-quarter revenues decrease to $5.6 million

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today reported financial and operating results for the second quarter ended June 30, 2010.

12 Aug 2010

NovoSeven RT in 8 mg vial for hemophilia A or B with inhibitors receives FDA approval

Novo Nordisk announced today that the U.S. Food and Drug Administration has approved NovoSeven® RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) in an 8 mg vial size, making the hemophilia A or B with inhibitors treatment available in 1, 2, 5 and 8 mg vials. The 8 mg vial allows a rapid initiation and administration of this medication for those patients who need a larger dose. In addition, FDA has also approved the extension of shelf life for all vial sizes from 24 months to 36 months at room temperature (at or below 77 degrees Fahrenheit).

11 Aug 2010

New volume on Growth hormone therapy

Growth hormone (GH) has been used therapeutically for over 50 years. Since the development of a nearly unlimited supply of recombinant human GH in the mid-1980s, children with less severe GH deficiency can also profit from GH replacement therapy.

5 Aug 2010

Study: hGH linked to PROLOR's CTP technology increases half-life, bioactivity

PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today reported publication of a preclinical study in the current on-line edition of the journal Endocrinology showing that human growth hormone (hGH) linked to PROLOR's carboxyl terminal peptide (CTP) technology has significantly increased half-life and bioactivity compared to commercially available hGH. The publication, which is authored by PROLOR researchers, will also be included in the September print edition of Endocrinology.

2 Aug 2010

SynCo Bio Partners extends collaboration with Versartis

SynCo Bio Partners today announced an extension of its successful collaboration with Versartis, Inc. following the recent initiation of a Phase 1 clinical trial in type 2 diabetes mellitus (T2DM) patients with monthly dosing of VRS-859. This news comes less than 12 months since the parties entered into a strategic partnership to manufacture Versartis' lead product VRS-859 (exenatide-XTEN).

30 Jul 2010

Growth Hormone News and Research

Further Reading

Aeterna Zentaris' AEZS-130 demonstrates potential as oral diagnostic test for AGHD

FDA grants orphan drug designation to hGH-CTP for treating growth hormone deficiency

Novo Nordisk announces $73M expansion of Clayton insulin delivery systems manufacturing facility

Human growth hormone can treat cystic fibrosis symptoms

Study may provide informed use of growth hormone in muscle development, muscle loss

Over one in three diabetics do not take insulin as prescribed

Dr. Shlomo Melmed awarded 9th Endocrine Regulation Prize of the Fondation Ipsen

Diplomat Specialty Pharmacy ranked #554 on Inc.'s Top 5000 list of fastest-growing private companies

Scientists develop new strategy for quicker detection of biomarkers that indicate disease

World's tallest man undergoes Gamma Knife surgery

Researchers recommend traumatic brain injury reclassification for additional funding

Access Pharmaceuticals to highlight Cobalamin nanotechnology at ACS National Meeting

FDA clears PROLOR Biotech's Phase II clinical trial of hGH-CTP

Novo Nordisk reaches exclusive agreement to market Vagifem 10 mcg

Antares Pharma second-quarter total revenue increases 78% to $3.1 million

Aeterna Zentaris second-quarter revenues decrease to $5.6 million

NovoSeven RT in 8 mg vial for hemophilia A or B with inhibitors receives FDA approval

New volume on Growth hormone therapy

Study: hGH linked to PROLOR's CTP technology increases half-life, bioactivity

SynCo Bio Partners extends collaboration with Versartis

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News